AAP
OVID icon

Arax Advisory Partners’s Ovid Therapeutics OVID Stock Holding History

Arax Advisory Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127 Hold
57
– – ﹤0.01% 3593
2025
Q4 		$93 Sell
57
-83
-59% -$128 ﹤0.01% 3839
2025
Q3 		$182 Buy
+140
New +$121 ﹤0.01% 3456

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Arax Advisory Partners's OVID Position: Q1 2026 in Review

Arax Advisory Partners held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 57 shares worth $127. The position accounts for ﹤0.01% of the portfolio, ranked #3593.

Arax Advisory Partners first reported a position in OVID in Q3 2025 and has held it in 3 quarters since. The position peaked at $182 in Q3 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Arax Advisory Partners held 57 shares of Ovid Therapeutics worth $127 as of Q1 2026.
  • Arax Advisory Partners left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3593 holding.
  • Arax Advisory Partners first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Ovid Therapeutics position peaked at $182 in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.